MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574545 | Name: ent-Abacavir

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ent-Abacavir is an enatiomer of Abacavir. Abacavir is a carbocyclic 2'-deoxyguanosine nucleoside reverse transcriptase inhibitor and an anti-HIV drug used to treat HIV infection. Intracellular enzymes convert Abacavir to its active form, carbovir-triphosphate (CBV-TP), which then selectively inhibits HIV reverse transcriptase by incorporating into viral DNA. Abacavir is metabolized in the liver by uridine diphosphate glucuronyltransferase and alcohol dehydrogenase resulting in inactive glucuronide and carboxylate metabolites, respectively.

Chemical Structure

ent-Abacavir
ent-Abacavir
CAS#136470-79-6

Theoretical Analysis

MedKoo Cat#: 574545

Name: ent-Abacavir

CAS#: 136470-79-6

Chemical Formula:

Exact Mass: 0.0000

Molecular Weight: 0.00

Elemental Analysis:

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ent-Abacavir; Abacavir EP Impurity A
IUPAC/Chemical Name
(1R,4S)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
InChi Key
MCGSCOLBFJQGHM-WCBMZHEXSA-N
InChi Code
InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m0/s1
SMILES Code
OC[C@H]1C=C[C@@H](N2C=NC3=C(NC4CC4)N=C(N)N=C23)C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Foster RH, Faulds D. Abacavir. Drugs. 1998 May;55(5):729-36; discussion 737-8. doi: 10.2165/00003495-199855050-00018. PMID: 9585869. 2: Pezzani MD, Resnati C, Di Cristo V, Riva A, Gervasoni C. Abacavir-induced liver toxicity. Braz J Infect Dis. 2016 Sep-Oct;20(5):502-4. doi: 10.1016/j.bjid.2016.03.002. Epub 2016 Apr 4. PMID: 27054757; PMCID: PMC9425524. 3: Somboonwit C, Kurtyka D, Velez AP. Abacavir and lamivudine combination. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1599-606. doi: 10.1517/17425250903439720. PMID: 19929448. 4: Christensen BL, Tan DH. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV. Expert Opin Pharmacother. 2022 Mar;23(4):439-446. doi: 10.1080/14656566.2022.2029409. Epub 2022 Jan 24. PMID: 35073817. 5: Llibre JM, Hill A. Abacavir and cardiovascular disease: A critical look at the data. Antiviral Res. 2016 Aug;132:116-21. doi: 10.1016/j.antiviral.2016.05.015. Epub 2016 May 31. PMID: 27260856. 6: Martin MA, Kroetz DL. Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3. PMID: 23649914; PMCID: PMC3700656. 7: Greig SL, Deeks ED. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6. Erratum in: Drugs. 2015 Apr;75(5):561. PMID: 25698454. 8: Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26. PMID: 18303141. 9: Hervey PS, Perry CM. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs. 2000 Aug;60(2):447-79. doi: 10.2165/00003495-200060020-00015. PMID: 10983741. 10: Comi L, Maggiolo F. Abacavir + dolutegravir + lamivudine for the treatment of HIV. Expert Opin Pharmacother. 2016 Oct;17(15):2097-106. doi: 10.1080/14656566.2016.1232387. Epub 2016 Sep 13. PMID: 27616133. 11: Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002 Oct;24(10):1502-14. doi: 10.1016/s0149-2918(02)80057-1. PMID: 12462283. 12: Vandekerckhove L, Blot S, Vogelaers D. Abacavir hypersensitivity. N Engl J Med. 2008 Jun 5;358(23):2514-5; author reply 2515-6. doi: 10.1056/NEJMc080541. PMID: 18525052. 13: Abel S, Paturel L, Cabié A. Abacavir hypersensitivity. N Engl J Med. 2008 Jun 5;358(23):2515; author reply 2515-6. PMID: 18536095. 14: Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep. 2010 Aug;7(3):127-33. doi: 10.1007/s11904-010-0047-3. PMID: 20521126. 15: Ibbotson T, Perry CM. Lamivudine/zidovudine/abacavir: triple combination tablet. Drugs. 2003;63(11):1089-98; discussion 1099-1100. doi: 10.2165/00003495-200363110-00010. PMID: 12749741. 16: Abacavir warning. AIDS Patient Care STDS. 2000 Nov;14(11):617. doi: 10.1089/10872910050193806. PMID: 11155904. 17: Keiser P, Nassar N. Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. Expert Opin Pharmacother. 2007 Mar;8(4):477-83. doi: 10.1517/14656566.8.4.477. PMID: 17309342. 18: Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71. doi: 10.2165/00003088-200847060-00001. PMID: 18479171. 19: Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs. 2005;65(2):285-302. doi: 10.2165/00003495-200565020-00010. PMID: 15631548. 20: Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002 Apr 15;34(8):1137-42. doi: 10.1086/339751. Epub 2002 Mar 19. PMID: 11915004.